Catalent to open new clinical supply facility in San Diego6 Sep 2019
Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.
Catalent is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.
The new 24,257-sq ft facility will offer full clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials. Its capabilities will include clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction, and will include stability chambers.
Located less than a mile from the company’s West Coast early-phase oral drug product development center of excellence, the new facility enhances Catalent’s OptiForm Total Supply service, offering customers fully integrated development, clinical supply manufacturing and distribution. This integrated approach helps customers minimize overall project risks and can significantly reduce the time taken to move a program from development into clinic.
“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies” commented Paul Hegwood, President, Clinical Supply Services. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the US and Canada’s drug development region.”
With sites in the US, UK, Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, and so help to expedite clinical trials by ensuring customers are reliably supplied where and when needed around the globe.
Catalent’s existing San Diego facility is one of three global centers of excellence in oral dose early-phase development focusing on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being in Somerset, New Jersey and Nottingham, UK.
Lilly to invest more than $470 million to build new manufacturing facility
22 Jan 2020
The new manufacturing site will be a state-of-the-art facility that produces injectable products and delivery devices.Read more
Grey Wolf Therapeutics secures funding for cancer therapies development
21 Jan 2020
The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.Read more
Diabetes diagnosis - now a matter of sweat and tears?
21 Jan 2020
No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.Read more
Forté Pharma strengthens cosmetics range with oral supplement launch
20 Jan 2020
Reig Jofre's oral, anti-wrinkle, moisturizing and firming cosmetic expands Forté Pharma's beauty range.Read more
Wuxi to acquire Bayer final drug product manufacturing site
17 Jan 2020
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities.Read more
Former Bosch drug packaging division renamed Syntegon
16 Jan 2020
Business to focus on intelligent and sustainable technologies.Read more
BioMarin gets go-ahead to start gene therapy clinical trials
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
Catalent launches direct-to-patient clinical supply services
14 Jan 2020
Multiple options provide increased flexibility for sponsors.Read more
Biogen to acquire novel clinical-stage asset from Pfizer
14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.Read more
French regulator agrees to partial resumption of Tellomak trial patient recruitment
14 Jan 2020
The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation